NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated
-- Agreement extends existing partnership -- -- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area and will greatly strengthen Helius’s presence in the region -- NEWTOWN, Pa., March 22, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc.
-- Full year 2022 revenue of $0.8 million, an increase of 51% over 2021 -- -- Year-end cash balance of $14.5 million -- -- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a
-- PoNS already approved in Canada for treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI) and gait deficit due to mild and moderate symptoms from Multiple Sclerosis (MS) -- NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc.
NEWTOWN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its
NEWTOWN, Pa., March 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief
Physical therapists in attendance can enhance their skillset with free on-site PoNS training NEWTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait
-- Q4 2022 revenue projected to range from $275,000 to $285,000 -- -- Full year 2022 revenue projected to range from $780,000 to $790,000 -- -- Unaudited year end cash balance of $14.5 million -- NEWTOWN, Pa., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc.
NEWTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer,
-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS ® therapy for gait improvement in Multiple Sclerosis -- NEWTOWN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Helius Medical